United-Guardian Inc

United-Guardian Inc(UG)の株式分析

$6.780

-0.020 (-0.29%)終値時点

Loading chart…
高値
6.885
始値
6.690
出来高加重平均価格
6.77
出来高
16.51K
時価総額
42.64M
安値
6.650
売買代金
111.82K
EV/EBITDA(TTM)
0.00

United-Guardian, Inc. is a manufacturer of cosmetic ingredients, sexual wellness ingredients, pharmaceuticals, and medical lubricants. The Company’s product lines include the Lubrajel line of multifunctional hydrogel formulations, which are designed to provide sensory enhancement, lubrication, hydration, and texture to both personal care and medical products. Its four distinct product categories include cosmetic ingredients, pharmaceuticals, medical lubricants and sexual wellness. Its COSMOS line of products includes Lubrajel Natural, Lubrajel Marine, Lubrajel Oil Natural, and Lubrajel Terra. Its medical lubricants include a line of hydrogel formulations designed to offer sensory enhancement and lubrication to medical products. The Company’s pharmaceutical products include an FDA-approved prescription drug that is used primarily to prevent and to dissolve calcifications in urethral catheters, as well as a chlorine-based topical antimicrobial.

u-g.com

AI分析 of United-Guardian Inc (UG)

中立

United-Guardian Inc is currently not a strong buy due to mixed performance indicators. The current price is $6.78, with an RSI of 40.69 indicating a neutral momentum. The forward P/E ratio is 26.53, suggesting that the stock may be overvalued relative to its earnings potential. However, the company has shown a year-to-date change of +10.60%, indicating some resilience. The main risk is the recent revenue decline of 13.5% year-over-year, attributed to market challenges, which could impact future profitability.

バリュエーション指標

United-Guardian Inc(UG)の現在の予想PERは26.53で、5年平均は4.61です。

予想PER

大幅な割高
5年平均 P/E
4.61
現在のP/E
26.53
割高
14.78
割安
-5.56

予想EV/EBITDA

大幅な割安
5年平均 EV/EBITDA
0.00
現在のEV/EBITDA
0.00
割高
0.00
割安
0.00

予想PSR

大幅な割安
5年平均 P/S
0.00
現在のP/S
0.00
割高
0.00
割安
0.00

Alphio AI による UG の価格シナリオ

シナリオ価格は本年の最終月次予想レンジです。確率はモデルの固定ウェイト(25 / 50 / 25)であり、保証ではありません。

強

強気

強気 · 25%UG

$13.06

シナリオ価格

基

基本

基本 · 50%UG

$11.05

シナリオ価格

弱

弱気

弱気 · 25%UG

$10.96

シナリオ価格

イベントタイムライン

2025-11-06 (ET)

09:04:50

United-Guardian Announces Q3 Earnings Per Share of 6 Cents Compared to 19 Cents Last Year

2025-08-08 (ET)

09:05:14

United-Guardian reports Q2 EPS 14c vs 21c

2025-05-21 (ET)

09:05:44

United-Guardian appoints Donna Vigilante to board of directors

2025-05-08 (ET)

09:03:12

United-Guardian reports Q1 EPS 12c vs 20c last year

2025-03-21 (ET)

09:04:32

United-Guardian reports FY24 EPS 71c vs 56c last year

ニュース

UG のよくある質問 — Alphio AI が回答

United-Guardian, Inc. is a manufacturer of cosmetic ingredients, sexual wellness ingredients, pharmaceuticals, and medical lubricants. The Company’s product lines include the Lubrajel line of multifunctional hydrogel formulations, which are designed to provide sensory enhancement, lubrication, hydration, and texture to both personal care and medical products. Its four distinct product categories include cosmetic ingredients, pharmaceuticals, medical lubricants and sexual wellness. Its COSMOS line of products includes Lubrajel Natural, Lubrajel Marine, Lubrajel Oil Natural, and Lubrajel Terra. Its medical lubricants include a line of hydrogel formulations designed to offer sensory enhancement and lubrication to medical products. The Company’s pharmaceutical products include an FDA-approved prescription drug that is used primarily to prevent and to dissolve calcifications in urethral catheters, as well as a chlorine-based topical antimicrobial. It operates in the Healthcare sector (PERFUMES, COSMETICS & OTHER TOILET PREPARATIONS industry).

United-Guardian Inc is currently not a strong buy due to mixed performance indicators. The current price is $6.78, with an RSI of 40.69 indicating a neutral momentum. The forward P/E ratio is 26.53, suggesting that the stock may be overvalued relative to its earnings potential. However, the company has shown a year-to-date change of +10.60%, indicating some resilience. The main risk is the recent revenue decline of 13.5% year-over-year, attributed to market challenges, which could impact future profitability.

コミュニティ

もっと見る ↗

投稿はまだありません

登録またはログインして議論に参加

関連記事

本ページは調査目的であり、投資助言ではありません。モデルは誤ることがあります。過去の実績は将来の成果を保証しません。

取引を始める